January 30th 2023
This review will explore various leukemia-related cutaneous findings and discuss the diagnosis and management of these conditions.
Leading Blastic Plasmacytoid Dendritic Cell Neoplasm Expert Perspective: Use Social Media for Breaking Research and Networking with Other BPDCN ExpertsOctober 21st 2022
A world leader in BPDCN explains how using social media can enhance dermatologists’ knowledge about this rare form of aggressive blood cancer.
Diagnosis, management challenging for pediatric BPDCNOctober 3rd 2022
A 13-year-old boy presenting an asymptotic dark violaceous infiltrated nodular lesion located on the left cheek was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy that often presents with skin manifestations.
Target therapies under study to treat BPDCNDecember 8th 2020
Researchers are looking at treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematolymphoid malignancy, with investigational agents equipped with different mechanisms of action, including XmAb14045 and IMGN632.
Venetoclax monotherapy for cutaneous BPDCNNovember 11th 2020
B-cell lymphoma-2 inhibitor venetoclax has shown in clinical studies to improve symptoms with minimal toxicity in patients with cutaneous blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer that can be rapidly fatal without treatment.
CD123-targeted therapies promising in BPDCN and AMLOctober 6th 2020
Several CD123-targeted therapies have been in development following the FDA’s 2018 approval of tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but important questions remain when it comes to targeting CD123 in myeloid malignancies.
Tagraxofusp treatment for BPDCN continues to evolveOctober 5th 2020
A recent paper details the different ways scientists are investigating tagraxofusp to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy that often presents with skin manifestations.
Tagraxofusp comparable to other chemo regimens as first-line therapySeptember 4th 2020
Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.
What dermatologists should know about blastic plasmacytoid dendritic cell neoplasmSeptember 3rd 2020
One expert who is part of a small worldwide group of dedicated scientists and clinicians working to build BPDCN awareness among specialists offers insights from his research for dermatologists.
FDA-approved treatment puts rare cancer with skin manifestations on the mapJuly 31st 2020
Those who study blastic plasmacytoid dendritic cell neoplasm (BPDCN) struggle to make dermatologists and others aware that the rare hematologic malignancy that often first presents with skin manifestations exists.
Anti-CD123-CAR T-cell therapy-radiotherapy combo effectively treats recurring blastic plasmacytoid dendritic cell neoplasmJuly 14th 2020
The 10-year-old male presented after experiencing five months of bilateral knee joint pain. A bone marrow smear and biopsy revealed the boy had blastic plasmacytoid dendritic cell neoplasm. Doctors treated him and the patient achieved complete remission. The patient presented with a scalp rash one month after his first complete remission.
Review highlights inroads to understanding blastic plasmacytoid dendritic cell neoplasmJuly 13th 2020
Studies are revealing clinical, molecular, diagnostic and therapeutic findings that are leading to a better understanding of blastic plasmacytoid dendritic cell neoplasm, and there are promising targeted treatments in the pipeline as well as a growing social media interest.
Genetic features pave way for targeted BPDCN therapiesJune 1st 2020
Dermatologists might be the first providers to encounter patients with blastic plasmacytoid dendritic cell neoplasm because more than 70% of these patients have cutaneous lesions. With one approved treatment and several in clinical trials, there are promising and much needed therapeutic options coming.
Investigational agents to treat hematologic malignancy in pipelineMay 4th 2020
Blastic plasmacytoid dendritic neoplasm (BPDCN) is a rare but aggressive hematologic malignancy that often manifests with asymptomatic skin lesions that often appear as bruise-like lesions, plaques or nodules. With one approved drug available, researchers are studying additional investigational agents.
Consider lesion biopsy in patients with history of certain cancersMay 4th 2020
While little is known about BPDCN and how to treat it, authors of a recent study suggest a low threshold for performing a skin biopsy to evaluate skin lesions in patients with hematological cancers, especially when those lesions that are quickly progressing, large or involve atypical sites.